Biophysical and Biochemical Approach to Locating an Inhibitor Binding Site on Cholesteryl Ester Transfer Protein

• Published in: Bioconjugate chemistry 2008-08, Vol.19 (8), p.1604-1613
• Main Authors: Cunningham, David, Lin, Wen, Hoth, Lise R, Danley, Dennis E, Ruggeri, Roger B, Geoghegan, Kieran F, Chrunyk, Boris A, Boyd, James G
• Format: Article
• Language: English
• Subjects: Affinity Labels - chemistry; Affinity Labels - metabolism; Binding Sites; Binding, Competitive; Biotin - metabolism; Cardiovascular disease; Cholesterol; Cholesterol Ester Transfer Proteins - antagonists & inhibitors; Cholesterol Ester Transfer Proteins - chemistry; Cholesterol Ester Transfer Proteins - genetics; Cholesterol Ester Transfer Proteins - metabolism; Crystal structure; Ligands; Lipids; Mass spectrometry; Mutagenesis; Plasma; Protein Binding; Proteins; Quinolines - chemistry; Quinolines - metabolism; Surface Plasmon Resonance - methods
• ISSN: 1043-1802; 1520-4812
• DOI: 10.1021/bc800165n

Cholesteryl ester transfer protein (CETP) transfers neutral lipids between different types of plasma lipoprotein. Inhibitors of CETP elevate the fraction of plasma cholesterol associated with high-density lipoproteins and are being developed as new agents for the prevention and treatment of cardiovascular disease. The molecular basis of their function is not yet fully understood. To aid in the study of inhibitor interactions with CETP, a torcetrapib-related compound was coupled to different biotin-terminated spacer groups, and the binding of CETP to the streptavidin-bound conjugates was monitored on agarose beads and in a surface plasmon resonance biosensor. CETP binding was poor with a 2.0 nm spacer arm, but efficient with polyethyleneglycol spacers of 3.5 or 4.6 nm. The conjugate based on a 4.6 nm spacer was used for further biosensor experiments. Soluble inhibitor blocked the binding of CETP to the immobilized drug, as did preincubation with a disulfide-containing covalent inhibitor. To provide a first estimate of the binding site for torcetrapib-like inhibitors, CETP was modified with a disulfide-containing agent that modifies Cys-13 of CETP. Mass spectrometry of the modified protein indicated that a single half-molecule of the disulfide was covalently bound to CETP, and peptide mapping after digestion with pepsin confirmed previous reports based on mutagenesis that Cys-13 was the site of modification. Modified CETP was unable to bind to the biosensor-mounted torcetrapib analog, indicating that the binding site on CETP for torcetrapib is in the lipid-binding pocket near the N-terminus of the protein. The crystal structure of CETP shows that the sulfhydryl group of Cys-13 resides at the bottom of this pocket.